'Study drug' diaporamas de présentation

Study drug - PowerPoint PPT Presentation


What’s New and What’s Next in the Treatment of MDS?

What’s New and What’s Next in the Treatment of MDS?

What’s New and What’s Next in the Treatment of MDS?. Mikkael A. Sekeres, MD, MS Professor of Medicine Director, Leukemia Program Vice Chair for Clinical Research Cleveland Clinic Cleveland, Ohio. David P. Steensma, MD, FACP Associate Professor of Medicine Harvard Medical School

By svea
(316 views)

Christopher S. Brazel, Ph.D., P.E.

Christopher S. Brazel, Ph.D., P.E.

Christopher S. Brazel, Ph.D., P.E. . Associate Professor: University of Alabama Department of Chemical and Biological Engineering. The University of Alabama College of Engineering Department of Chemical and Biological Engineering.

By darcie
(159 views)

BMT CTN 0302 Randomized Phase II Trial of Four Acute GVHD Therapies

BMT CTN 0302 Randomized Phase II Trial of Four Acute GVHD Therapies

HCT (BM, PBSC, CB). Acute GVHD (diagnosed in past 48 hours). Yes, requiring systemic therapy. No. RANDOMIZATION. Prednisone, and Etanercept , or MMF*, or Ontak, or Pentostatin . If progressive GVHD within 7 days, or no response within 14 days, treat

By lorelei
(306 views)

2011 US Diabetes Statistics

2011 US Diabetes Statistics

2011 US Diabetes Statistics. Diabetes affects 25.8 million people in the US (8.3% of the U.S. population) 18.8 million diagnosed, 7.0 million undiagnosed 10.9 million (26.9%) of those aged ≥65 have diabetes 215,000 people <20

By hayley
(71 views)

Efficacy Results from Three Pivotal Efficacy Trials

Efficacy Results from Three Pivotal Efficacy Trials

Efficacy Results from Three Pivotal Efficacy Trials. Karl F. Mann, M.D. Professor and Chairman Director, Department of Addictive Behavior and Addiction Medicine Central Institute of Mental Health of Mannheim University of Heidelberg. Pivotal European Efficacy Studies - Objective.

By sari
(244 views)

Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Rot

Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Rot

Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in Hyperlipidemic Subjects: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled Study. Dirk Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Lesley Burgess, Richard Ceska , Eli Roth,

By brenna
(195 views)

The Bangkok Tenofovir Study

The Bangkok Tenofovir Study

Bangkok Metropolitan Administration. Thailand Ministry of Public Health. The Bangkok Tenofovir Study. An HIV pre-exposure prophylaxis trial in Thailand: participant adherence and study results .

By armand
(206 views)

Bashi Ratterree, RN, BSN, CCRP

Bashi Ratterree, RN, BSN, CCRP

Bashi Ratterree, RN, BSN, CCRP Nurse Coordinator, CHM OHSU Knight Cancer Institute Mail code: UHN73C 503-494-9982 ratterre@ohsu.edu. A Phase II Trial of the Safety and Efficacy of Abc-001 for the Treatment of CoordinatorStressitis. Adverse Events Reporting Exercise. 2 yr trial

By debbie
(150 views)

CAB Draft Discussion Tuesday, January 14, 2014 CWRU/UH CRS CAB Meeting

CAB Draft Discussion Tuesday, January 14, 2014 CWRU/UH CRS CAB Meeting

A5336 A Phase IIa , Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults. CAB Draft Discussion Tuesday, January 14, 2014 CWRU/UH CRS CAB Meeting. Inflammation.

By trevor
(235 views)

Funding: The TRACER trial was funded by Merck & Co., Inc.

Funding: The TRACER trial was funded by Merck & Co., Inc.

Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Non–ST-Segment Elevation Acute Coronary Syndrome Patients in TRACER.

By arty
(82 views)

Randomization & Consent Scenarios

Randomization & Consent Scenarios

Randomization & Consent Scenarios. Deneil Harney MPH, MSW HSP Coordinator University of Michigan. Randomization Scenarios.

By nay
(104 views)

Lilliam Rosario, Ph.D. Director Office of Computational Science

Lilliam Rosario, Ph.D. Director Office of Computational Science

JumpStart the Regulatory Review:  Applying the Right Tools at the Right Time to the Right Audience. Lilliam Rosario, Ph.D. Director Office of Computational Science. Agenda. Office of Computational Science Who we are What we do CSC Reviewer Services Data and Analysis

By wolfe
(114 views)

How to Evaluate a Randomized Clinical Trial ( RCT ): What Every Pharmacist Should Know

How to Evaluate a Randomized Clinical Trial ( RCT ): What Every Pharmacist Should Know

How to Evaluate a Randomized Clinical Trial ( RCT ): What Every Pharmacist Should Know . Pharmacists often need to review primary literature to make patient specific recommendation or apply information to clinical practice.

By malha
(190 views)

Renee Stapleton 7/07/05

Renee Stapleton 7/07/05

Developing a Phase II RCT: The effects of n-3 fatty acids on lung and systemic inflammation in patients with acute lung injury. Renee Stapleton 7/07/05. Outline. Choosing a research question and selecting study design Process of designing the trial Timeline Budget Lessons learned.

By reed
(71 views)

Prilosec1 ® 20 mg Tablets Rx to OTC Switch

Prilosec1 ® 20 mg Tablets Rx to OTC Switch

Prilosec1 ® 20 mg Tablets Rx to OTC Switch. Daiva Shetty, M.D. Division of Over-the-Counter Drug Products (HFD-560) Food and Drug Administration. 1. Prilosec1 ® Rx to OTC Switch: Overview. Regulatory History Proposed Label Target Population Actual Use Study #007. 2.

By eshana
(121 views)

Overview of Investigational Drug Services and Study Drug Accountability

Overview of Investigational Drug Services and Study Drug Accountability

Overview of Investigational Drug Services and Study Drug Accountability. Merrell Lim, Pharm.D. Investigational Drug Services Pharmacist mlim1@clarian.org 317-944-1900. Learning Objectives. Learn about services provided by investigational drug services (IDS) pharmacy

By lieu
(363 views)

Definitions, Scaling & Graphs

Definitions, Scaling & Graphs

Definitions, Scaling & Graphs. I. Definitions. Variable – something that can take on more than one value Independent variable – explains or causes Dependent variable explained or effect. Example Sex Eye color Class standing Age Height Weight Visualization SAT-Verbal Curiosity.

By don
(107 views)

Statistical Review

Statistical Review

Statistical Review. Dr. Shan Sun-Mitchell. ENT 00-02 Primary endpoint: Time to treatment failure by day 50. Placebo BDP Patients randomized 67 62 Number of treatment failures 30(45%) 18 (29%)

By mercia
(101 views)

Did that just happen? And What do I do now?

Did that just happen? And What do I do now?

Did that just happen? And What do I do now?. Identifying and Reporting Adverse Events and Protocol Deviations. Elizabeth Mathis, CCRP 18 February 2014. Adverse Events Serious Adverse Events Protocol Deviations. Overview and Objectives. http://www.hhs.gov/ohrp/policy/advevntguid.html.

By helmut
(137 views)

Adverse Event Reporting

Adverse Event Reporting

Adverse Event Reporting. Reporting Adverse Events. Adverse Events (AEs) are “. . . any untoward medical occurrence in a subject that was not previously identified which does not necessarily have a causal relationship to the study drug…”

By ketan
(327 views)

View Study drug PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Study drug PowerPoint presentations. You can view or download Study drug presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.